Health Condition 1: O- Medical and Surgical
Conditions
Interventions
Intervention1: Intravenous Lignocaine: Intravenous lignocaine in a dose of 1.5 mg/kg bolus over 10 minutes prior to induction of anesthesia followed by 2.0 mg/kg/hour until skin closure using a progra
Sponsors
Dr Zainab Ahmad
Eligibility
Inclusion criteria
Inclusion criteria: ASA physical status I- to II, with operable breast cancer Stage I to III
Exclusion criteria
Exclusion criteria: Metastatic or recurrent breast cancer, significant comorbidities, contraindications to lignocaine, pregnancy, weight less than 40 kg, preoperative hypotension, immune disorders, or long-term immunosuppressive drug use.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum levels NETosis biomarkers - H3CitTimepoint: Baseline and at 24 hours after surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| Early cancer recurrenceTimepoint: 2 years or until the end of the study;Angiogenesis Biomarkers - MMP 3, VEGFTimepoint: baseline and at 24 hours after surgery.;Changes in arrays of metabolomic profile and hypoxia inducible factors (HIF)Timepoint: baseline and at 24 hours after surgery.;Serum MPO levelsTimepoint: baseline & 24 hours after surgery | — |
Countries
India
Contacts
Public ContactDr Jagat Kanwar
All India Institute of Medical Sciences (AIIMS), Bhopal
Outcome results
None listed